Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib

A number of CML patients who achieve a sustained complete molecular response (CMR) for at least 2 years during imatinib (IM) therapy can discontinue IM without relapse. With the long‐term goal of developing immunological criteria for managing IM therapy in CML patients, we compared the immunophenoty...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Sci
Prif Awduron: Mizoguchi, Izuru, Yoshimoto, Takayuki, Katagiri, Seiichiro, Mizuguchi, Junichiro, Tauchi, Tetsuzo, Kimura, Yukihiko, Inokuchi, Koiti, Ohyashiki, Junko H., Ohyashiki, Kazuma
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2013
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656535/
https://ncbi.nlm.nih.gov/pubmed/23758044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12216
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg